Eli Lilly is expanding operations in its home state of Indiana, announcing a $2.1 billion investment for two new manufacturing sites.
The sites will be located at the LEAP Lebanon Innovation and Research District in Boone County, Indiana, and will help “support increased demand for existing Lilly products and play a key role in bringing Lilly's robust clinical pipeline to patients around the world” the company said in a statement this week.
Lilly’s most recent win has been its diabetes drug Mounjaro. The drug, a first-in-class dual-action med that is injected once a week and activates glucose and insulin receptors in the body, was approved by the FDA earlier this month.
This recent approval and other site announcements made this year hint at a successful 2022 for the pharma company. The new sites in Indiana are expected to create 500 new jobs, adding to the 3,700 workers Lilly already employs in the state. The proposed project will also create close to 1,500 construction jobs.